<div id="readability-page-1"><ul><li>Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher</li></ul><p>PepGen, Inc. (NASDAQ:PEPG - Free Report) - Equities research analysts at Wedbush lifted their FY2025 EPS estimates for shares of PepGen in a research note issued on Wednesday, November 12th. Wedbush analyst L. Chico now anticipates that the company will earn ($2.25) per share for the year, up from their previous forecast of ($2.44). Wedbush has a &#34;Outperform&#34; rating and a $9.00 price target on the stock. The consensus estimate for PepGen's current full-year earnings is ($2.73) per share. Wedbush also issued estimates for PepGen's Q4 2025 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.35) EPS, Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.32) EPS, FY2027 earnings at ($1.21) EPS and FY2028 earnings at ($1.18) EPS.</p><p>PepGen (NASDAQ:PEPG - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.11. </p><ul><li>PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data</li></ul><p>Other equities research analysts have also recently issued reports about the stock. HC Wainwright boosted their price target on shares of PepGen from $18.00 to $20.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday. Guggenheim  reiterated a &#34;buy&#34; rating and set a $6.00 target price on shares of PepGen in a research report on Wednesday, September 24th. Stifel Nicolaus boosted their target price on PepGen from $9.00 to $12.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, September 25th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of PepGen in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded PepGen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday. Four analysts have rated the stock with a Buy rating and two have assigned  a Sell rating to the stock. According to data from MarketBeat, PepGen currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $10.00.</p><p><b>Check Out Our Latest Analysis on PEPG</b></p><h2>PepGen Stock Performance</h2><p>PEPG opened at $4.74 on Monday. PepGen has a one year low of $0.88 and a one year high of $6.85. The company has a market cap of $155.47 million, a P/E ratio of -1.68 and a beta of 1.95. The business's 50-day simple moving average is $4.00 and its 200-day simple moving average is $2.29. </p><h2>Insiders Place Their Bets</h2><p>In other PepGen news, major shareholder Science Enterprises Plc Oxford purchased 200,000 shares of the stock in a transaction dated Tuesday, September 30th. The shares were acquired at an average cost of $3.20 per share, for a total transaction of $640,000.00. Following the completion of the transaction, the insider directly owned 4,955,388 shares of the company's stock, valued at $15,857,241.60. This trade represents a 4.21% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own  4.60% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of  PepGen during the 1st quarter worth about $25,000.  ADAR1 Capital Management LLC purchased a new position in  PepGen in the first quarter valued at approximately $29,000.  Rangeley Capital LLC lifted its position in  PepGen by 133.3% during the second quarter. Rangeley Capital LLC now owns 35,000 shares of the company's stock valued at $39,000 after buying an additional 20,000 shares in the last quarter.  Marshall Wace LLP acquired a new position in  PepGen during the second quarter valued at approximately $44,000.  Finally, Burkehill Global Management LP purchased a new stake in  PepGen during the third quarter worth approximately $46,000. 58.01% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>About PepGen</h2> (Get Free Report)<p>PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.</p><h2>See Also</h2><ul><li>Five stocks we like better than PepGen</li><li>How to Calculate Return on Investment (ROI)</li><li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li><li>How is Compound Interest Calculated?</li><li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li><li>3 Healthcare Dividend Stocks to Buy</li><li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVQRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UEVQRw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in PepGen Right Now?</h2><p>Before you consider PepGen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.</p><p>While PepGen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PEPG

<p>Wedbush analysts have raised their FY2025 EPS estimates for PepGen, Inc. from ($2.44) to ($2.25) per share. The firm maintains an "Outperform" rating and a $9.00 price target on the stock. Other analysts have also issued positive ratings, with price targets ranging from $6.00 to $20.00. PepGen's recent quarterly earnings beat consensus estimates, and the stock has seen significant insider and institutional investment.</p>

What is Wedbush's Forecast for PepGen FY2025 Earnings?